Aerie Pharmaceuticals closes $30 million Series B financing Aerie Pharmaceuticals.

Aerie Pharmaceuticals closes $30 million Series B financing Aerie Pharmaceuticals, Inc, a biotechnology company centered on the discovery and development of medical improvements in ophthalmology, today announced the closing of a $30 million Series B financing. Clarus Ventures and Sofinnova Ventures co-led the circular, with participation from Osage University Companions, and existing investors Alta Companions and TPG Biotech. Aerie expects to use arises from this financing to fund continued development of Aerie’s broad product portfolio in glaucoma and progress the business’s lead product, AR-12286, a first-in-course selective Rho-kinase inhibitor, into Stage 3 trials by the ultimate end of 2011.This serum is certainly voted as one of the best hair products of 2012-13. It is an excellent alternative to minoxidil-infused hair regrowth treatment. Females, who are pregnant or breastfeeding, are suggested by doctors in order to avoid minoxidil make use of. Moreover, there are females who may use minoxidil, but wish never to undergo any serious treatment for hair growth. For these social people, the follicle boosting serum is an ideal product. Experts have concluded that it is safe for females of most ages and for use on all sorts of hair. It is high time this serum was utilized by you and reaped its miraculous benefits.